PwC Middle East's Voice of the Consumer 2025 survey covered Saudi Arabia, the UAE, Qatar and more, with 9% of respondents tied to GLP-1s.
Recap by typeshit. Post by Fast Company Middle East on X.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
Gottlieb also covers the FDA's new Rare Disease Framework Initiative and the latest on the measles outbreak in the CNBC interview.
Loading…